Promise Ball 2014

2014PromiseBall_SaveTheDate-FINAL

                                                                                                                    

 

JDRF Promise Ball Raises Approximately

$1.2 Million for Diabetes Research

The North Central CT / Western MA and Greater New Haven Chapters of JDRF hosted their 2013 Promise Ball, Building Toward a Cure, on May 11 at the Connecticut Convention Center in Hartford.  The event attracted more than 550 guests from across Connecticut and Massachusetts and raised over $1.2 million for research to find a cure for type 1 diabetes and its complications. The organization is still receiving donations and expects the number of dollars raised to increase.

John F. Lundgren, Chairman and Chief Executive Officer of Stanley Black & Decker, accepted the Star of Hope Award on behalf of the company for their commitment to the Foundation’s mission. Dr. Kevan Herold of Yale University also received the Star of Hope award for his investigative work in the area of diabetes prevention and treatment. NBC Connecticut’s Gerry Brooks served as Emcee of the Ball.

Jonathan Muskrat, JDRF Executive Director, commented “JDRF is extremely grateful to leaders like John Lundgren and Dr. Kevan Herold, and to all of those who have shown their support of our organization. The commitment to helping improve the lives of people with type 1 diabetes is truly inspiring and provides hope for a future without this disease.”

The 2013 Fund-A-Cure Family, Kevin, Rebecca (Becka) and Ryan Morris, were the evening’s featured speakers and received an emotional standing ovation from the audience after sharing what it is like to live with the disease.  Both Becka and Ryan live with T1D. Their remarks were followed by JDRF’s signature Fund A Cure program, during which 100% tax-deductible donations were made toward research.  The whopping $475,000 raised during the Fund A Cure portion of the evening will go directly toward funding JDRF’s Beta Cell Regeneration project. The focus of the project is on the creation of insulin producing beta cells to replace those destroyed in the autoimmune attack, in an environment where that attack can never happen again. JDRF is leading the way in funding research aimed at overcoming these obstacles.